[Hearing impairment in children with cystic fibrosis]

A I Kryukov1, A Yu Ivoilov1, N A Mileshina2

  • 1Sverzhevsky Research Clinical Institute of Otorhinolaryngology, Moscow, Russia.

PubMed

Insights

Cystic fibrosis patients may experience hearing loss due to aminoglycoside antibiotics. Inflammatory issues also contribute to hearing impairment in children with cystic fibrosis, necessitating further auditory function studies.

Area of Science:

  • Pediatric Otolaryngology
  • Medical Genetics
  • Pharmacology

Background:

  • Hearing impairment is a significant concern in children with cystic fibrosis (CF).
  • Systemic antibacterial therapy, particularly with aminoglycoside antibiotics, is frequently used in CF management.
  • The ototoxic effects of aminoglycosides pose a risk to auditory function in this vulnerable population.

Purpose of the Study:

  • To investigate the causes of hearing loss in children with cystic fibrosis.
  • To analyze the impact of aminoglycoside antibiotic therapy on auditory function in pediatric CF patients.
  • To identify specific risk factors for hearing impairment in this cohort.

Main Methods:

  • A comprehensive literature search was conducted.
  • Databases utilized included PubMed, Web of Science, and eLibrary.
  • The review focused on studies examining hearing function in relation to CF and its treatments.

Main Results:

  • Aminoglycoside use is linked to sensorineural hearing loss in CF patients.
  • Inflammatory processes in the middle ear and eustachian tube predict conductive hearing loss.
  • Aminoglycoside therapy does not universally cause hearing impairment, highlighting individual variability.

Conclusions:

  • Further research is crucial to understand the nuances of hearing impairment in children with CF.
  • Identifying specific characteristics of hearing loss can inform targeted interventions.
  • Monitoring auditory function is essential for children undergoing treatment for cystic fibrosis.